» Articles » PMID: 24398230

The Annual Global Economic Burden of Heart Failure

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2014 Jan 9
PMID 24398230
Citations 375
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heart failure (HF) imposes both direct costs to healthcare systems and indirect costs to society through morbidity, unpaid care costs, premature mortality and lost productivity. The global economic burden of HF is not known.

Methods: We estimated the overall cost of heart failure in 2012, in both direct and indirect terms, across the globe. Existing country-specific heart failure costs analyses were expressed as a proportion of gross domestic product and total healthcare spend. Using World Bank data, these proportional values were used to interpolate the economic cost of HF for countries of the world where no published data exists. Countries were categorized according to their level of economic development to investigate global patterns of spending.

Results: 197 countries were included in the analysis, covering 98.7% of the world's population. The overall economic cost of HF in 2012 was estimated at $108 billion per annum. Direct costs accounted for ~60% ($65 billion) and indirect costs accounted for ~40% ($43 billion) of the overall spend. Heart failure spending varied widely between high-income and middle and low-income countries. High-income countries spend a greater proportion on direct costs: a pattern reversed for middle and low-income countries.

Conclusions: Heart failure imposes a huge economic burden, estimated at $108 billion per annum. With an aging, rapidly expanding and industrializing global population this value will continue to rise.

Citing Articles

Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population.

Zou X, He X, Shi Q, Wang S, Li N, Zhou Y Front Pharmacol. 2025; 16:1527972.

PMID: 40070563 PMC: 11893398. DOI: 10.3389/fphar.2025.1527972.


Demographics and regional trends of ischemic heart disease-related mortality in older adults in the United States, 1999-2020.

Latif F, Moiz Nasir M, Rehman W, Hamza M, Mattumpuram J, Meer K PLoS One. 2025; 20(1):e0318073.

PMID: 39854527 PMC: 11760020. DOI: 10.1371/journal.pone.0318073.


Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis.

Naves M, Amato A, Zimmermann I, Peixoto H Lancet Reg Health Am. 2025; 42():100968.

PMID: 39835255 PMC: 11742827. DOI: 10.1016/j.lana.2024.100968.


Trends in Avoidable Hospitalizations for Heart Failure in Switzerland (1998-2018): A Cross-Sectional Analysis.

Gaillard L, Maung K, Mauron C, Marques-Vidal P, Gouveia A Healthcare (Basel). 2025; 12(24.

PMID: 39765974 PMC: 11675926. DOI: 10.3390/healthcare12242547.


Evaluation of health-related quality of life changes in an Australian rapid access chest pain clinic.

Black J, Sharman J, Chen G, Palmer A, de Graaff B, Nelson M BMC Health Serv Res. 2025; 25(1):8.

PMID: 39748242 PMC: 11697740. DOI: 10.1186/s12913-024-12135-0.